HLA-G and neoplasm: Moreover, our data also indicated that the secreted Nb‐BiTE also could disrupt PD‐L1‐mediated inhibition to reinforce NK‐induced cytolysis to tumor cells as well.[49] Accordingly, embedding a secretable PD‐L1‐targeting Nb‐BiTE into the Nb‐CAR construct should overcome PD‐L1‐mediated resistance to CAR‐T therapy and potentiate the efficacy of HLA‐G‐targeted Nb‐CAR to combat solid tumors.